Stem bark extract of Mangifera indica prevents testosterone-induced benign prostate hyperplasia in rats
Main Article Content
Abstract
Background: Benign prostate hyperplasia (BPH) is one of the most common conditions affecting up to 80% of th men in their 8 decade of life. Mangifera indica Linn stem bark is used in traditional African medicine for the treatment of cancer, prostate hyperplasia, prostatitis and diabetes.
Objective: This study sought to investigate the effect of hydroethanolic stem bark extract of Mangifera indica (MI) on testosterone-induced BPH in rats.
Methods: BPH was induced in male albino rats (200-250g; n=8) through subcutaneous injection of testosterone propionate (3 mg/kg, in 10% olive oil) for 4 weeks. MI (100, 200 or 400 mg/kg, p.o.) or vehicle (10 ml/kg, p.o.) was administered 15 min before testosterone injection. On day 29, the animals were anaesthetized and blood collected for estimation of serum testosterone and prostate specific antigen (PSA). The prostates were excised, weighed and subjected to biochemical and histological studies.
Results: subcutaneous injection of testosterone caused significant increase in prostate weight (2.83 folds), prostatic index (3.24 folds), serum testosterone (2.29 folds) and PSA (1.83 fold) levels indicative of BPH which was ameliorated by pretreatment of rats with MI. Testosterone also increased malondialdehyde (MDA) level but decreased glutathione, superoxide dismutase and catalase activities indicating oxidative stress which was attenuated by MI treatment. The alteration in the morphology of the prostate induced by testosterone was prevented by MI administration.
Conclusion: The results obtained from this study showed that Mangifera indica stem bark extract prevented testosterone-induced BPH through enhancement of antioxidant defense mechanisms. Thus, could be a potential phytotherapeutic agent in the management of BPH.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology 148(5): 1549-57.
O'Leary MP. (2003). Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 62(3 Suppl 1):15-23
Vital P, Castro P, Ittmann M. (2016). Oxidative stress promotes benign prostatic hyperplasia. Prostate 76(1):58-67.
Carson C 3rd, Rittmaster R. (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61(4 Suppl 1):2-7.
Pej?i? T, Tosti T, Teši? Ž, Milkovi? B, Dragi?evi? D, Kozomara M, ?ekerevac M, Džami? Z. (2017). Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume. Prostate. doi: 10.1002/pros.23365.
Aryal M, Pandeya A, Gautam N, Baral N, Lamsal M, Majhi S, Chandra L, Pandit R, Das BK. (2007). Oxidative stress in benign prostate hyperplasia. Nepal Medical College Journal 9(4):222-4.
Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S. (2015). Oxidative stress in benign prostatic hyperplasia: a systematic review. Urology International 2015; 94(3):249-54.
Schulman CC. (2003). Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology
(3 Suppl 1):24-33.
Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, Joshi G, Khan SA. (2017). The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Translational Andrology and Urology 6(2):295-304.
Burkill HM. (1997). The Useful Plants of West Tropical Africa. (Second Edition). Volume 4. Families M-R. Royal Botanic Gardens, Kew, Richmond, United Kingdom.
Shah KA, Patel MB, Patel RJ. (2010). Mangifera ndica (mango): Pharmacognosy Review 4(7): 42-48.
Oluwole OG, Esume C. (2015). Anti-inflammatory effects of aqueous extract of Mangifera indica in Wistar rats. Journal of Basic and Clinical Physiology and Pharmacology 26(3):313-5.
Awodele O, Adeneye AA, Aiyeola SA, Benebo AS. (2015). Modulatory effect of Mangifera indica against carbon tetrachloride induced kidney damage in rats. Interdisciplinary Toxicology 8(4):175-83
Adeneye AA, Awodele O, Aiyeola SA, Benebo AS. (2015). Modulatory potentials of the aqueous stem bark extract of Mangifera indica on carbon tetrachloride-induced hepatotoxicity in rats. Journal of Traditional and Complementary Medicine. 5(2):106-15.
Ishola IO, Awodele O, Eluogu CO. (2016). Potentials of Mangifera indica in the treatment of depressiveanxiety disorders: possible mechanisms of action. Journal of Complementary and Integrative Medicine 13(3):275-287
Khurana RK, Kaur R, Lohan S, Singh KK, Singh B. (2016). Mangiferin: a promising anticancer bioactive. Pharmaceutical patent analyst 5(3):169-81.
Singh R, Singh SK, Maharia RS, Garg AN. (2015). Identification of new phytoconstituents and antimicrobial activity in stem bark of Mangifera indica (L.). Journal of Pharmaceutical and Biomedical Analyst 105:150-5.
Barreto JC, Trevisan MT, Hull WE, Erben G, de Brito ES, Pfundstein B, et al. (2008). Characterization and quantitation of polyphenolic compounds in bark, kernel, leaves, and peel of mango (Mangifera indica L.). Journal of Agricultural Food and Chemistry 56:5599-610.
Spiridon L, Bodirlau R, Teaca CA. (2011). Total phenolic content and antioxidant activity of plants used in traditional Romanian herbal medicine. Central European Journal of Biology 6(3):388-396.
Zhishen J, Mengcheng T, Jianming W. (1999). The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals. Food Chemistry 64:555-559.
Ishola IO, Akinyede AA, Robert AK, Omilabu SA. (2015). Hepatoprotective and antioxidant activities of Hepacare®, a herbal formulation
against carbon tetrachloride-induced liver injury. Drug Research (Stuttg) 65(1):30-9.
Ishola IO, Akindele JA, Adeyemi OO. (2012).Subchronic toxicity (90 days) study of the methanol root extract of Cnestis ferruginea. Pharmaceutical Biology 50 (8): 994 -1006.
Ishola IO, Tota S, Adeyemi OO, Agbaje EO, Narender T, Shukla R. (2013). Protective effect of Cnestis ferruginea and its active constituent on scopolamine-induced memory impairment in mice: A behavioral and biochemical study. Pharmaceutical Biology 51(7):825-35.
Acute Oral Toxicity (OECD Test Guideline 425) 2001. Statistical Programme (AOT425StatPgm)http://www.oecd.org/oecd/pag
es/home/displaygeneral/0, 3380, EN-document-524-nodirectorate-no-24-6775-8,FF.html Version 1.0.
Ohkawa H, Ohishi N, Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 95(2):351-8.
Sedlak J, Lindsay RH. (1968). Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Analytical Biochemistry 25(1):192-205.
Winterbourn CC, Benatti U, De Flora A. (1986). Contributions of superoxide, hydrogen peroxide, and transition metal ions to auto oxidation of the favism-inducing pyrimidine aglycone, divicine, and its reactions with haemoglobin. Biochemical Pharmacology 35(12):2009-15.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry
(1):265-75.
Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E. (2009). Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Review of Urology Spring 11(2):82-107
Veeresh Babu SV, Veeresh B, Patil AA, Warke YB. (2010). Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. European Journal of Pharmacology 626(2-3):262-5
Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. (1982). Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Journal of Urology 128(4):836-9
Ishola IO, Tijani HK, Dosumu OO, Anunobi CC, Oshodi TO. (2017). Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-? and cyclo-oxygenase-2. Fundamental and Clinical Pharmacology 31(6):652-662
Ishola IO, Yemitan KO, Afolayan OO, Anunobi CC, Durojaiye TE. (2018). Potential of Moringa oleifera in the Treatment of Benign Prostate Hyperplasia: Role of Antioxidant Defence Systems. Medical Principle and Practice 27(1):15-22.
Narayanan NK, Nargi D, Horton L, Reddy BS, Bosland MC, Narayanan BA. (2009). Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 69(2):133-41
Ishola IO, Anunobi CC, Tijani KH, Afolayan O, Udokwu VU. (2017). Potential of telmisartan in the treatment of benign prostatic hyperplasia. Fundamental and Clinical Pharmacology 31(6):643-651
Aydin A, Arsova-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgok Y, Dimovski A. (2006). Oxidative stress and antioxidant status in nonmetastatic prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry 39(2):176-9.
Udensi UK, Tchounwou PB. (2016). Oxidative stress in prostate hyperplasia and carcinogenesis. Journal of Experimental and Clinical Cancer Research 35(1):139.
Tan LT, Chan KG, Khan TM, Bukhari SI, Saokaew S, Duangjai A, Pusparajah P, Lee LH, Goh BH. (2017). Streptomyces sp. MUM212 as a Source of Antioxidants with Radical Scavenging and Metal Chelating Properties. Frontiers in Pharmacology 8:276.
Huie RE, Padmaja S. (1993). The reaction of no with superoxide. Free Radical Research Communication 18(4):195-9
Ishola IO, Agbaje EO, Adeyemi OO, Shukla R. (2014). Analgesic and anti-inflammatory effects of the methanol root extracts of some selected Nigerian medicinal plants. Pharmaceutical Biology 52(9):1208-16.